507 related articles for article (PubMed ID: 17094454)
1. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
Binnie MC; Alexander FE; Heald C; Habib FK
Prostate; 2005 Jun; 63(4):309-15. PubMed ID: 15599941
[TBL] [Abstract][Full Text] [Related]
3. Novel polymorphisms in prostate specific antigen gene and its association with prostate cancer.
Yang Q; Shan L; Segawa N; Nakamura M; Nakamura Y; Mori I; Sakurai T; Kakudo K
Anticancer Res; 2001; 21(1A):197-200. PubMed ID: 11299734
[TBL] [Abstract][Full Text] [Related]
4. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
Chiang CH; Chen KK; Chang LS; Hong CJ
J Urol; 2004 Apr; 171(4):1529-32. PubMed ID: 15017213
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci.
Xue W; Irvine RA; Yu MC; Ross RK; Coetzee GA; Ingles SA
Cancer Res; 2000 Feb; 60(4):839-41. PubMed ID: 10706090
[TBL] [Abstract][Full Text] [Related]
6. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
[TBL] [Abstract][Full Text] [Related]
7. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
[TBL] [Abstract][Full Text] [Related]
8. Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men.
Schatzl G; Madersbacher S; Gsur A; Preyer M; Haidinger G; Haitel A; Vutuc C; Micksche M; Marberger M
Prostate; 2002 Jul; 52(2):130-8. PubMed ID: 12111704
[TBL] [Abstract][Full Text] [Related]
9. Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells.
Medeiros R; Morais A; Vasconcelos A; Costa S; Pinto D; Oliveira J; Carvalho R; Lopes C
Prostate; 2002 Sep; 53(1):88-94. PubMed ID: 12210484
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
11. ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population.
Kalay E; Ergen A; Narter F; Agaçhan B; Görmüs U; Yigit N; Isbir T
Anticancer Res; 2009 Apr; 29(4):1395-8. PubMed ID: 19414393
[TBL] [Abstract][Full Text] [Related]
12. Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort.
Xue WM; Coetzee GA; Ross RK; Irvine R; Kolonel L; Henderson BE; Ingles SA
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):575-9. PubMed ID: 11401905
[TBL] [Abstract][Full Text] [Related]
13. Decoy androgen-responsive element DNA can inhibit androgen receptor transactivation of the PSA promoter gene.
Zhang P; Zhang J; Young CY; Kao PC; Chen W; Jiang A; Zhang L; Guo Q
Ann Clin Lab Sci; 2005; 35(3):278-84. PubMed ID: 16081584
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
15. Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer.
Das K; Cheah PY; Lim PL; Zain YB; Stephanie FC; Zhao Y; Cheng C; Lau W
Cancer Lett; 2008 Sep; 268(2):340-7. PubMed ID: 18495332
[TBL] [Abstract][Full Text] [Related]
16. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer.
Kuasne H; Rodrigues IS; Fuganti PE; Losi-Guembarovski R; Ito K; Kishima MO; Rodrigues MA; Rogatto SR; Santos RM; Cólus IM
Cancer Invest; 2010 Nov; 28(9):917-24. PubMed ID: 20632874
[TBL] [Abstract][Full Text] [Related]
18. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells.
Tsui KH; Feng TH; Lin CM; Chang PL; Juang HH
J Androl; 2008; 29(6):661-8. PubMed ID: 18676361
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
Rabbani F; Perrotti M; Bastar A; Fair WR
J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
[TBL] [Abstract][Full Text] [Related]
20. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Majumdar S; Diamandis EP
Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
